Associate Professor Jennifer Byrne

Associate Professor
Paediatrics & Child Health, Children's Hospital, Westmead

Telephone +61 2 9845 3027
Fax +61 2 9845 3078

Website Related website

Map

Biographical details

Jennifer Byrne has spent her scientific career analyzing childhood and adult cancers at a molecular level. Her PhD studies mapped loss of chromosome 11p15 loci in embryonal tumours, and she then identified a novel gene family during postdoctoral studies in France. Jennifer is now Head of the Children’s Cancer Research Unit at the Children’s Hospital at Westmead, and Associate Professor within the Discipline of Paediatrics and Child Health at the University of Sydney.

Research interests

A/Prof Byrne's research interests include the functions of amplification target genes which are overexpressed in multiple cancers, predictive biomarker analyses in paediatric solid tumours, and improving cancer biobank operations.

Selected grants

2015

  • Ultra high performance liquid chromatography (UPLC) system; Liddle C, Byrne J, George J, Robinson P, Gunton J; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2014

  • Semi-automatic Tissue Microarrayer with digital image integration for enhancement of cancer research within the Sydney West Hub; Clarke C, Carpenter J, Mann G, DeFazio A, George J, Pathmanathan N, Byrne J, Graham D; Cancer Institute New South Wales/Equipment Grant.
  • NanoString nCounter Platform; deFazio A, Alexander I, Booth D, Byrne J, Christodoulou J, Clarke C, Cunningham A, George J, Graham J, Harman A, Liddle C, Mann G; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • A UPLC QTOF to improve cancer treatment and outcomes; Nath C, Shaw P, Trotman J, Larsen S, Gurney H, Byrne J, Haber M, Norris M, Marshall G, Munns C; Cancer Institute New South Wales/Equipment Grant.

2013

  • Automated in situ analysis capacity for translational cancer research; Byrne J, Reddel R, Haber M, Norris M, deFazio A; Cancer Institute New South Wales/Equipment Grant.
  • Fluidigm BioMark HD - HX; Alexander I, Jamieson R, Chircop (nee Fabbro) M, Byrne J, Catchpoole D, Reddel R, Tam P, Robinson P, Bryan T, Diefenbach R; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2009

  • Increased tumor protein D52 expression as a marker of breast cancer predispoition, and a possible role in DNA repair; Byrne J; DVC Research/Cancer Research Fund.
  • The molecular basis of cell transformation produced by TPD52 overexpression; Byrne J, Bright R, Smith B, Catchpoole D; Cancer Council New South Wales/Research Project Grants.

2007

  • Flow Cytometry support; Alexander S, Braithwaite A, Bradstock K, Bendall L, Gunning P, Henderson B, Kefford R, Reddel R, Rizos H, Jones C, Byrne J; Cancer Institute New South Wales/Infrastructure Grant.

2005

  • Cancer InstNSW Fell05-Byrne; Byrne J; Cancer Institute New South Wales/Research Grant.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Kamili, A., Byrne, J. (2014). Lipidomics in breast cancer. In Debmalya Barh (Eds.), Omics Approaches in Breast Cancer: Towards Next-Generation Diagnosis, Prognosis and Therapy, (pp. 225-244). New Delhi: Springer.
  • Della-Franca, A., Chen, Y., Byrne, J. (2012). TPD52 (Tumor Protein D52). In Sangdun Choi (Eds.), Encyclopaedia of Signalling Molecules, (pp. 1906-1911). New York: Springer.
  • Weidenhofer, J., Byrne, J. (2009). Isolation of nucleic acids from hard tissues. In Dongyou Liu (Eds.), Handbook of Nucleic Acid Purification, (pp. 427-448). Sydney, Australia: CRC Press.

Journals

  • Rush, A., Spring, K., Byrne, J. (2015). A critical analysis of cancer biobank practices in relation to biospecimen quality. Biophysical Reviews, 7(4), 369-378. [More Information]
  • Rush, A., Christiansen, J., Farrell, J., Goode, S., Scott, R., Spring, K., Byrne, J. (2015). Biobank classification in an Australian setting. Biopreservation and Biobanking, 13(3), 212-218. [More Information]
  • Saletta, F., Dalla-Pozza, L., Byrne, J. (2015). Genetic causes of cancer predisposition in children and adolescents. Translational Pediatrics, 4(2), 65-66. [More Information]
  • Small, A., Thwe, L., Byrne, J., Lau, L., Chan, A., Craig, M., Cowell, C., Garnett, S. (2015). Neuroblastoma, body mass index, and survival: a retrospective analysis. Medicine, 94(14), 1-6. [More Information]
  • Byrne, J., Wu, Z. (2015). Preface. Translational Pediatrics, 4(2), 65-66. [More Information]
  • Carter, D., Murray, J., Cheung, B., Gamble, L., Koach, J., Tsang, J., Sutton, S., Kalla, H., Syed, S., Gifford, A., Byrne, J., Thwe, L., et al (2015). Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Science Translational Medicine, 8, 1-11. [More Information]
  • Kamili, A., Roslan, N., Frost, S., Cantrill, L., Wang, D., Austin, D., Bright, R., Groblewski, G., Straub, B., Hoy, A., Chen, Y., Byrne, J. (2015). TPD52 expression increases neutral lipid storage within cultured cells. Journal of Cell Science, 128(17), 3223-3238. [More Information]
  • Shahheydari, H., Frost, S., Smith, B., Groblewski, G., Chen, Y., Byrne, J. (2014). Identification of PLP2 and RAB5C as novel TPD52 binding partners through yeast two-hybrid screening. Molecular Biology Reports, 41(7), 4565-4572. [More Information]
  • Saletta, F., Wadham, C., Ziegler, D., Marshall, G., Haber, M., McCowage, G., Norris, M., Byrne, J. (2014). Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clinical, 1, 59-77. [More Information]
  • Bright, R., Bright, J., Byrne, J. (2014). Overexpressed oncogenic tumor-self antigens: New vaccine targets. Human Vaccines & Immunotherapeutics, 10(11), 3297-3305. [More Information]
  • Biesemann, C., Gronborg, M., Luquet, E., Wichert, S., Bernard, V., Bungers, S., Cooper, B., Varoqueaux, F., Li, L., Byrne, J., et al (2014). Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting. The EMBO Journal, 33(2), 157-170. [More Information]
  • Roslan, N., Bièche, I., Bright, R., Lidereau, R., Chen, Y., Byrne, J. (2014). TPD52 Represents a Survival Factor in ERBB2-Amplified Breast Cancer Cells. Molecular Carcinogenesis, 53(10), 807-819. [More Information]
  • Byrne, J., Frost, S., Chen, Y., Bright, R. (2014). Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumor Biology, 35(8), 7369-7382. [More Information]
  • Bright, J., Aldrich, J., Byrne, J., Bright, R. (2014). Vaccination with the Prostate Cancer Over-Expressed Tumor Self-Protein TPD52 Elicits Protective Tumor Immunity and a Potentially Unique Subset of CD8+ T Cells. Austin Journal of Clinical Immunology, 1(2), 1-13.
  • Bright, J., Schultz, H., Byrne, J., Bright, R. (2013). Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen. OncoImmunology, 2(7), 1-11. [More Information]
  • Messenger, S., Thomas, D., Falkowski, M., Byrne, J., Gorelick, F., Groblewski, G. (2013). Tumor protein D52 controls trafficking of an apical endolysosomal secretory pathway in pancreatic acinar cells. American Journal of Physiology: Gastrointestinal and Liver Physiology, 305(6), G439-G452. [More Information]
  • Chen, Y., Kamili, A., Hardy, J., Groblewski, G., Khanna, K., Byrne, J. (2013). Tumor protein D52 represents a negative regulator of ATM protein levels. Cell Cycle, 12(18), 3083-3097. [More Information]
  • Byrne, J., Chen, Y., Martin La Rotta, N., Peters, G. (2012). Challenges in Identifying Candidate Amplification Targets in Human Cancers: Chromosome 8q21 as a Case Study. Genes and Cancer, 3(2), 87-101. [More Information]
  • Machado, I., Lopez-Guerrero, J., Calabuig-Farinas, S., Hardy, J., Scotlandi, K., Picci, P., Byrne, J., Llombart-Bosch, A. (2011). Clinical significance of tumor protein D52 immunostaining in a large series of Ewing's sarcoma family of tumors. Pediatric and Developmental Pathology, 14(3), 255-256. [More Information]
  • Della-Franca, A., Byrne, J. (2011). TPD52 (tumor protein D52). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 15(06), 483-489. [More Information]
  • Andres-Delgado, L., Anton, O., Madrid, R., Byrne, J., Alonso, M. (2010). Formin INF2 regulates MAL-mediated transport of Lck to the plasma membrane of human T lymphocytes. Blood, 116(26), 5919-5929. [More Information]
  • de Bock, C., Lin, Z., Mekkawy, A., Byrne, J., Wang, Y. (2010). Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. International Journal of Oncology, 36(5), 1155-1163. [More Information]
  • Byrne, J., Maleki, S., Hardy, J., Gloss, B., Murali, R., Scurry, J., Fanayan, S., Emmanuel, C., Hacker, N., Sutherland, R., deFazio, A., et al (2010). MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer, 10(497), 1-11. [More Information]
  • Madrid, R., Aranda, J., Rodriguez-Fraticelli, A., Ventimiglia, L., Andres-Delgado, L., Shehata, M., Fanayan, S., Shahheydari, H., Gomez, S., Jimenez, A., Byrne, J., et al (2010). The formin INF2 regulates basolateral-to-apical transcytosis and lumen formation in association with Cdc42 and MAL2. Developmental Cell, 18(5), 814-827. [More Information]
  • Thomas, D., Martin, C., Weng, N., Byrne, J., Groblewski, G. (2010). Tumor protein D52 expression and Ca2+-dependent phosphorylation modulates lysosomal membrane protein trafficking to the plasma membrane. American Journal of Physiology: Cell Physiology, 298(3), C725-C739. [More Information]
  • Lewis, J., Sullivan, L., Byrne, J., De Riese, W., Bright, R. (2009). Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunology, Immunotherapy: other biological response modifications, 58(8), 1337-1349. [More Information]
  • Fanayan, S., Shehata, M., Agterof, A., McGuckin, M., Alonso, M., Byrne, J. (2009). Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells. BMC Cell Biology, 10, 7-1-7-13. [More Information]
  • Alagaratnam, S., Hardy, J., Lothe, R., Skotheim, R., Byrne, J. (2009). TPD52, a candidate gene from genomic studies, is overexpressed in testicular germ cell tumours. Molecular And Cellular Endocrinology, 306(1-2), 75-80. [More Information]
  • Shehata, M., Bie'che, I., Boutros, R., Weidenhofer, J., Fanayan, S., Spalding, L., Zeps, N., Bright, R., Byth Wilson, K., Lidereau, R., Byrne, J. (2008). Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52. Clinical Cancer Research, 14(16), 5050-5060. [More Information]
  • Shehata, M., Weidenhofer, J., Thamotharampillai, K., Hardy, J., Byrne, J. (2008). Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays. Critical Reviews in Oncogenesis, 14(1), 23-44. [More Information]
  • Payton, L., Lewis, J., Byrne, J., Bright, R. (2008). Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunology, Immunotherapy: other biological response modifications, 57(6), 799-811. [More Information]
  • Lewis, J., Payton, L., Whitford, J., Byrne, J., Smith, D., Yang, L., Bright, R. (2007). Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Molecular Cancer Research, 5(2), 133-144.
  • Barbaric, D., Byth Wilson, K., Dalla-Pozza, L., Byrne, J. (2006). Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: Clinical and sample considerations. Leukemia Research: clinical and laboratory studies, 30(11), 1355-1363. [More Information]
  • Boutros, R., Byrne, J. (2005). D53 (TPD52L1) is a cell cycle-regulated protein maximally expressed at the G2-M transition in breast cancer cells. Experimental Cell Research, 310(1), 152-165. [More Information]
  • Shehata, M., Boutros, R., Bright, R., Byrne, J. (2005). In vitro models for tumor protein d52 function in cancer cells. Breast Cancer Research, 7(Suppl 2), S37-S37.
  • Tiacci, E., Orvietani, P., Corthals, G., Liso, A., Pileri, S., Byrne, J., Falini, B. (2005). TPD52: A novel B cell/plasma cell protein characterized by unique expression pattern and Ca+2-dependent association with annexin VI. Annals of Oncology, 16(Supplement 5), v78-v78.
  • Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 117(6), 1049-54. [More Information]
  • Tiacci, E., Orvietani, P., Bigerna, B., Pucciarini, A., Corthals, G., Pettirossi, V., Martelli, M., Liso, A., Benedetti, R., Byrne, J., et al (2005). Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca 2+-dependent association with annexin VI. Blood, 105(7), 2812-2820. [More Information]
  • Rubin, M., Varambally, S., Beroukhim, R., Tomlins, S., Rhodes, D., Paris, P., Hofer, M., Storz-Schweizer, M., Kuefer, R., et, A., Byrne, J. (2004). Overexpression, Amplification, And Androgen Regulation Of TPD52 In Prostate Cancer. Cancer Research, 64(11), 3814-3822.
  • Boutros, R., Fanayan, S., Shehata, M., Byrne, J. (2004). The Tumor Protein D52 Family: Many Pieces, Many Puzzles. Biochemical and Biophysical Research Communications, 325(4), 1115-1121.
  • Boutros, R., Bailey, A., Wilson, S., Byrne, J. (2003). Alternative splicing as a mechanism for regulating 14-3-3 binding: interactions between hD53 (TPD52L1) and 14-3-3 proteins. Journal of Molecular Biology, 332(3), 675-687.
  • Barbaric, D., Dalla-Pozza, L., Byrne, J. (2002). A reliable method of total RNA extraction from frozen human bone marrow samples taken at diagnosis of acute leukaemia. Journal of Clinical Pathology, 55(11), 865-867.
  • de Marco, M., Martin-Belmonte, F., Kremer, L., Albar, J., Correas, I., Vaerman, J., Marazuela, M., Byrne, J., Alonso, M. (2002). MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells. The Journal of Cell Biology, 159(1), 37-44.
  • Sum, E., Peng, B., Yu, X., Chen, J., Byrne, J., Lindeman, G., Visvader, J. (2002). The LIM doman protein LM04 interacts with the cofactor CtIP and the tumour suppressor BRCA1 and inhibits BRCA1 activity. Journal of Biological Chemistry, 277(10), 7849-7856.
  • Wilson, S., Bailey, A., Nourse, C., Mattei, M., Byrne, J. (2001). Identification of MAL2, a novel member of the MAL proteolipid family, though interactions with TPD52-like proteins in the yeast two-hybrid system. Genomics, 76(1-3), 81-88.
  • Sathasivam, P., Bailey, A., Crossley, P., Byrne, J. (2001). The role of the coiled-coil motif in interactions mediated by TPD52. Biochemical and Biophysical Research Communications, 288(1), 56-61.
  • Balleine, R., Schoenberg Fejzo, M., Sathasivam, P., Basset, P., Clarke, C., Byrne, J. (2000). The hD52 (TDP52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes and Cancer, 29(1), 48-57.

2015

  • Rush, A., Spring, K., Byrne, J. (2015). A critical analysis of cancer biobank practices in relation to biospecimen quality. Biophysical Reviews, 7(4), 369-378. [More Information]
  • Rush, A., Christiansen, J., Farrell, J., Goode, S., Scott, R., Spring, K., Byrne, J. (2015). Biobank classification in an Australian setting. Biopreservation and Biobanking, 13(3), 212-218. [More Information]
  • Saletta, F., Dalla-Pozza, L., Byrne, J. (2015). Genetic causes of cancer predisposition in children and adolescents. Translational Pediatrics, 4(2), 65-66. [More Information]
  • Small, A., Thwe, L., Byrne, J., Lau, L., Chan, A., Craig, M., Cowell, C., Garnett, S. (2015). Neuroblastoma, body mass index, and survival: a retrospective analysis. Medicine, 94(14), 1-6. [More Information]
  • Byrne, J., Wu, Z. (2015). Preface. Translational Pediatrics, 4(2), 65-66. [More Information]
  • Carter, D., Murray, J., Cheung, B., Gamble, L., Koach, J., Tsang, J., Sutton, S., Kalla, H., Syed, S., Gifford, A., Byrne, J., Thwe, L., et al (2015). Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Science Translational Medicine, 8, 1-11. [More Information]
  • Kamili, A., Roslan, N., Frost, S., Cantrill, L., Wang, D., Austin, D., Bright, R., Groblewski, G., Straub, B., Hoy, A., Chen, Y., Byrne, J. (2015). TPD52 expression increases neutral lipid storage within cultured cells. Journal of Cell Science, 128(17), 3223-3238. [More Information]

2014

  • Shahheydari, H., Frost, S., Smith, B., Groblewski, G., Chen, Y., Byrne, J. (2014). Identification of PLP2 and RAB5C as novel TPD52 binding partners through yeast two-hybrid screening. Molecular Biology Reports, 41(7), 4565-4572. [More Information]
  • Kamili, A., Byrne, J. (2014). Lipidomics in breast cancer. In Debmalya Barh (Eds.), Omics Approaches in Breast Cancer: Towards Next-Generation Diagnosis, Prognosis and Therapy, (pp. 225-244). New Delhi: Springer.
  • Saletta, F., Wadham, C., Ziegler, D., Marshall, G., Haber, M., McCowage, G., Norris, M., Byrne, J. (2014). Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clinical, 1, 59-77. [More Information]
  • Bright, R., Bright, J., Byrne, J. (2014). Overexpressed oncogenic tumor-self antigens: New vaccine targets. Human Vaccines & Immunotherapeutics, 10(11), 3297-3305. [More Information]
  • Biesemann, C., Gronborg, M., Luquet, E., Wichert, S., Bernard, V., Bungers, S., Cooper, B., Varoqueaux, F., Li, L., Byrne, J., et al (2014). Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting. The EMBO Journal, 33(2), 157-170. [More Information]
  • Roslan, N., Bièche, I., Bright, R., Lidereau, R., Chen, Y., Byrne, J. (2014). TPD52 Represents a Survival Factor in ERBB2-Amplified Breast Cancer Cells. Molecular Carcinogenesis, 53(10), 807-819. [More Information]
  • Byrne, J., Frost, S., Chen, Y., Bright, R. (2014). Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumor Biology, 35(8), 7369-7382. [More Information]
  • Bright, J., Aldrich, J., Byrne, J., Bright, R. (2014). Vaccination with the Prostate Cancer Over-Expressed Tumor Self-Protein TPD52 Elicits Protective Tumor Immunity and a Potentially Unique Subset of CD8+ T Cells. Austin Journal of Clinical Immunology, 1(2), 1-13.

2013

  • Bright, J., Schultz, H., Byrne, J., Bright, R. (2013). Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen. OncoImmunology, 2(7), 1-11. [More Information]
  • Messenger, S., Thomas, D., Falkowski, M., Byrne, J., Gorelick, F., Groblewski, G. (2013). Tumor protein D52 controls trafficking of an apical endolysosomal secretory pathway in pancreatic acinar cells. American Journal of Physiology: Gastrointestinal and Liver Physiology, 305(6), G439-G452. [More Information]
  • Chen, Y., Kamili, A., Hardy, J., Groblewski, G., Khanna, K., Byrne, J. (2013). Tumor protein D52 represents a negative regulator of ATM protein levels. Cell Cycle, 12(18), 3083-3097. [More Information]

2012

  • Byrne, J., Chen, Y., Martin La Rotta, N., Peters, G. (2012). Challenges in Identifying Candidate Amplification Targets in Human Cancers: Chromosome 8q21 as a Case Study. Genes and Cancer, 3(2), 87-101. [More Information]
  • Della-Franca, A., Chen, Y., Byrne, J. (2012). TPD52 (Tumor Protein D52). In Sangdun Choi (Eds.), Encyclopaedia of Signalling Molecules, (pp. 1906-1911). New York: Springer.

2011

  • Machado, I., Lopez-Guerrero, J., Calabuig-Farinas, S., Hardy, J., Scotlandi, K., Picci, P., Byrne, J., Llombart-Bosch, A. (2011). Clinical significance of tumor protein D52 immunostaining in a large series of Ewing's sarcoma family of tumors. Pediatric and Developmental Pathology, 14(3), 255-256. [More Information]
  • Della-Franca, A., Byrne, J. (2011). TPD52 (tumor protein D52). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 15(06), 483-489. [More Information]

2010

  • Andres-Delgado, L., Anton, O., Madrid, R., Byrne, J., Alonso, M. (2010). Formin INF2 regulates MAL-mediated transport of Lck to the plasma membrane of human T lymphocytes. Blood, 116(26), 5919-5929. [More Information]
  • de Bock, C., Lin, Z., Mekkawy, A., Byrne, J., Wang, Y. (2010). Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. International Journal of Oncology, 36(5), 1155-1163. [More Information]
  • Byrne, J., Maleki, S., Hardy, J., Gloss, B., Murali, R., Scurry, J., Fanayan, S., Emmanuel, C., Hacker, N., Sutherland, R., deFazio, A., et al (2010). MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer, 10(497), 1-11. [More Information]
  • Madrid, R., Aranda, J., Rodriguez-Fraticelli, A., Ventimiglia, L., Andres-Delgado, L., Shehata, M., Fanayan, S., Shahheydari, H., Gomez, S., Jimenez, A., Byrne, J., et al (2010). The formin INF2 regulates basolateral-to-apical transcytosis and lumen formation in association with Cdc42 and MAL2. Developmental Cell, 18(5), 814-827. [More Information]
  • Thomas, D., Martin, C., Weng, N., Byrne, J., Groblewski, G. (2010). Tumor protein D52 expression and Ca2+-dependent phosphorylation modulates lysosomal membrane protein trafficking to the plasma membrane. American Journal of Physiology: Cell Physiology, 298(3), C725-C739. [More Information]

2009

  • Weidenhofer, J., Byrne, J. (2009). Isolation of nucleic acids from hard tissues. In Dongyou Liu (Eds.), Handbook of Nucleic Acid Purification, (pp. 427-448). Sydney, Australia: CRC Press.
  • Lewis, J., Sullivan, L., Byrne, J., De Riese, W., Bright, R. (2009). Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunology, Immunotherapy: other biological response modifications, 58(8), 1337-1349. [More Information]
  • Fanayan, S., Shehata, M., Agterof, A., McGuckin, M., Alonso, M., Byrne, J. (2009). Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells. BMC Cell Biology, 10, 7-1-7-13. [More Information]
  • Alagaratnam, S., Hardy, J., Lothe, R., Skotheim, R., Byrne, J. (2009). TPD52, a candidate gene from genomic studies, is overexpressed in testicular germ cell tumours. Molecular And Cellular Endocrinology, 306(1-2), 75-80. [More Information]

2008

  • Shehata, M., Bie'che, I., Boutros, R., Weidenhofer, J., Fanayan, S., Spalding, L., Zeps, N., Bright, R., Byth Wilson, K., Lidereau, R., Byrne, J. (2008). Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52. Clinical Cancer Research, 14(16), 5050-5060. [More Information]
  • Shehata, M., Weidenhofer, J., Thamotharampillai, K., Hardy, J., Byrne, J. (2008). Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays. Critical Reviews in Oncogenesis, 14(1), 23-44. [More Information]
  • Payton, L., Lewis, J., Byrne, J., Bright, R. (2008). Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunology, Immunotherapy: other biological response modifications, 57(6), 799-811. [More Information]

2007

  • Lewis, J., Payton, L., Whitford, J., Byrne, J., Smith, D., Yang, L., Bright, R. (2007). Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Molecular Cancer Research, 5(2), 133-144.

2006

  • Barbaric, D., Byth Wilson, K., Dalla-Pozza, L., Byrne, J. (2006). Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: Clinical and sample considerations. Leukemia Research: clinical and laboratory studies, 30(11), 1355-1363. [More Information]

2005

  • Boutros, R., Byrne, J. (2005). D53 (TPD52L1) is a cell cycle-regulated protein maximally expressed at the G2-M transition in breast cancer cells. Experimental Cell Research, 310(1), 152-165. [More Information]
  • Shehata, M., Boutros, R., Bright, R., Byrne, J. (2005). In vitro models for tumor protein d52 function in cancer cells. Breast Cancer Research, 7(Suppl 2), S37-S37.
  • Tiacci, E., Orvietani, P., Corthals, G., Liso, A., Pileri, S., Byrne, J., Falini, B. (2005). TPD52: A novel B cell/plasma cell protein characterized by unique expression pattern and Ca+2-dependent association with annexin VI. Annals of Oncology, 16(Supplement 5), v78-v78.
  • Byrne, J., Balleine, R., Fejzo, M., Mercieca, J., Chiew, Y., Livnat, Y., St.Heaps, L., Peters, G., Byth Wilson, K., Karlan, B., Harnett, P., deFazio, A., et al (2005). Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 117(6), 1049-54. [More Information]
  • Tiacci, E., Orvietani, P., Bigerna, B., Pucciarini, A., Corthals, G., Pettirossi, V., Martelli, M., Liso, A., Benedetti, R., Byrne, J., et al (2005). Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca 2+-dependent association with annexin VI. Blood, 105(7), 2812-2820. [More Information]

2004

  • Rubin, M., Varambally, S., Beroukhim, R., Tomlins, S., Rhodes, D., Paris, P., Hofer, M., Storz-Schweizer, M., Kuefer, R., et, A., Byrne, J. (2004). Overexpression, Amplification, And Androgen Regulation Of TPD52 In Prostate Cancer. Cancer Research, 64(11), 3814-3822.
  • Boutros, R., Fanayan, S., Shehata, M., Byrne, J. (2004). The Tumor Protein D52 Family: Many Pieces, Many Puzzles. Biochemical and Biophysical Research Communications, 325(4), 1115-1121.

2003

  • Boutros, R., Bailey, A., Wilson, S., Byrne, J. (2003). Alternative splicing as a mechanism for regulating 14-3-3 binding: interactions between hD53 (TPD52L1) and 14-3-3 proteins. Journal of Molecular Biology, 332(3), 675-687.

2002

  • Barbaric, D., Dalla-Pozza, L., Byrne, J. (2002). A reliable method of total RNA extraction from frozen human bone marrow samples taken at diagnosis of acute leukaemia. Journal of Clinical Pathology, 55(11), 865-867.
  • de Marco, M., Martin-Belmonte, F., Kremer, L., Albar, J., Correas, I., Vaerman, J., Marazuela, M., Byrne, J., Alonso, M. (2002). MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells. The Journal of Cell Biology, 159(1), 37-44.
  • Sum, E., Peng, B., Yu, X., Chen, J., Byrne, J., Lindeman, G., Visvader, J. (2002). The LIM doman protein LM04 interacts with the cofactor CtIP and the tumour suppressor BRCA1 and inhibits BRCA1 activity. Journal of Biological Chemistry, 277(10), 7849-7856.

2001

  • Wilson, S., Bailey, A., Nourse, C., Mattei, M., Byrne, J. (2001). Identification of MAL2, a novel member of the MAL proteolipid family, though interactions with TPD52-like proteins in the yeast two-hybrid system. Genomics, 76(1-3), 81-88.
  • Sathasivam, P., Bailey, A., Crossley, P., Byrne, J. (2001). The role of the coiled-coil motif in interactions mediated by TPD52. Biochemical and Biophysical Research Communications, 288(1), 56-61.

2000

  • Balleine, R., Schoenberg Fejzo, M., Sathasivam, P., Basset, P., Clarke, C., Byrne, J. (2000). The hD52 (TDP52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosomes and Cancer, 29(1), 48-57.

To update your profile click here. For support on your academic profile contact .